Stocktoria
ADIAL PHARMACEUTICALS, INC. ADIL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-07-27
ADIAL PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $2.6M | $3.2M | $1.3M | $2.0M | $8.4M |
| Operating income | -$7.8M | -$8.3M | -$6.9M | -$10.9M | -$19.3M |
| Income tax | — | — | — | -$502 | -$94,077 |
| Net income | -$8.0M | -$13.2M | -$5.1M | -$12.7M | -$19.4M |
| EPS (diluted) | $-11.93 | $-68.01 | $-3.60 | $-12.71 | $-1.04 |
| Operating cash flow | -$6.5M | -$6.9M | -$6.8M | -$11.2M | -$11.9M |
| Free cash flow | — | — | — | — | -$12.0M |
| Cash & equivalents | $5.9M | $3.8M | $2.8M | $4.0M | $6.1M |
| Total assets | $6.7M | $5.0M | $4.7M | $5.7M | $7.5M |
| Total liabilities | $1.4M | $975,858 | $653,076 | $2.5M | $4.0M |
| Shareholders' equity | $5.3M | $4.1M | $4.1M | $3.3M | $3.5M |
Source: SEC EDGAR filings · CIK 0001513525 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.